Abstract
Special populations of T helper cells drive B cells to produce IgG class switched, pathogenic autoantibodies in lupus. The major source of antigenic determinants (epitopes) that trigger interactions between lupus T and B cells is nucleosomes of apoptotic cells. These epitopes can be used for antigen-specific therapy of lupus. Secondly, the autoimmune T cells of lupus are sustained because they resist anergy and activation-induced programmed cell death by markedly upregulating cyclooxygenase (COX) 2 along with the antiapoptotic molecule c-FLIP. Only certain COX-2 inhibitors block pathogenic anti-DNA autoantibody production in lupus by causing death of autoimmune T helper cells. Hence COX-2 inhibitors may work independently of their ability to block the enzymatic function of COX-2, and structural peculiarities of these select inhibitors may lead to better drug discovery and design.
Similar content being viewed by others
Abbreviations
- APC :
-
Antigen-presenting cell
- Cbl :
-
Cassitus B lymphoma oncogene
- CD40L :
-
CD40 ligand
- c-FLIP :
-
Cellular Fas-associated death domain-like interleukin 1β converting enzyme inhibitory protein
- COX :
-
Cyclooxygenase
- DC :
-
Dendritic cell
- ERK :
-
Extracellular signal regulated kinase
- FADD :
-
Fas-associated death domain
- FasL :
-
Fas ligand
- IAP :
-
Inhibitor of apoptosis protein
- IL :
-
Interleukin
- PG :
-
Prostaglandin
- SLE :
-
Systemic lupus erythematosus
- TCR :
-
T cell receptor
- Th :
-
T helper
References
Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD (1995) Systemic lupus erythematosus: emerging concepts. I. Renal, neuropschyatric, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 122:940–950
Datta SK, Patel H, Berry D (1987) Induction of a cationic shift in IgG anti-DNA autoantibodies. Role of T helper cells with classical and novel phenotypes in three murine models of lupus nephritis. J Exp Med 165:1252–1268
Shivakumar S, Tsokos GC, Datta SK (1989) T cell receptor alpha/beta expressing double negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 143:103–112
Naiki M, Chiang B-L, Cawley D, Ansari A, Rozzo SJ, Kotzin BL, Zlotnik A, Gershwin ME (1992) Generation and characterization of cloned helper T cell lines for anti-DNA responses in NZB.H-2bm12 mice. J Immunol 149:4109–4115
Singh RR, Kumar V, Ebling FM, Southwood S, Sette A, Sercarz EE, Hahn BH (1995) T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine SLE. J Exp Med 181:2017–2027
Zeng D, Lee MK, Tung J, Brendolan A, Strober S (2000) Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol 164:5000–5004
Datta SK, Schwartz RS (1976) Genetics of expression of xenotropic virus and autoimmunity in NZB mice. Nature 263:412–415
Sainis K, Datta SK (1988) CD4+ T cell lines with selective patterns of autoreactivity as well as CD4-/CD8-T helper cell lines augment the production of idiotypes shared by pathogenic anti-DNA autoantibodies in the NZB x SWR model of lupus nephritis. J Immunol 140:2215–2224
Rajagopalan S, Zordan T, Tsokos GC, Datta SK (1990) Pathogenic anti-DNA autoantibody inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-/CD8-T helper cell lines that express the gd T-cell receptor. Proc Natl Acad Sci USA 87:7020–7024
Adams S, Leblanc P, Datta SK (1991) Junctional region sequences of T-cell receptor b chain genes expressed by pathogenic anti-DNA autoantibody-inducing T helper cells from lupus mice: possible selection by cationic autoantigens. Proc Natl Acad Sci USA 88:11271–11275
Shi Y, Kaliyaperumal A, Lu L, Southwood S, Sette A, Michaels MA, Datta SK (1998) Promiscuous presentation and recognition of nucleosomal autoepitopes in lupus: role of autoimmune T cell receptor alpha chain. J Exp Med 187:367–378
Mohan C, Adams S, Stanik V, Datta SK (1993) Nucleosome: a major immunogen for the pathogenic autoantibody-inducing T cells of lupus. J Exp Med 177:1367–1381
Kaliyaperumal A, Mohan C, Wu W, Datta SK (1996) Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 183:2459–2469
Voll RE, Roth EA, Girkontaite I, Fehr H, Herrman M, Lorenz HM, Kalden JR (1997) Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum 40:2162–2171
Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F (2000) Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 43:2307–2315
Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555–556
Casciola-Rosen LA, Anhalt G, Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317–1330
Shoshan Y, Mevorach D (2004) Accelerated autoimmune disease in MRL/MpJ-Fas (lpr) but not inMRL/MpJ following immunization with high load of sysngeneic late apoptotic cells. Autoimmunity 37:103–109
Bondanza A, Zimmermann VS, Dell’Antonio G, Dal Cin E, Capobianco A, Sabbadini MG, Manfredi AA, Rovere-Querini P (2003) Cutting edge: dissociation between autoimmune response and clinical disease after vaccination with dendritic cells. J Immunol 170:24–27
Kaliyaperumal A, Michaels MA, Datta SK (2002) Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. J Immunol 168:2530–2537
Lu L, Kaliyaperumal A, Boumpas DT, Datta SK (1999) Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 104:345–355
Wu HY, Ward FJ, Staines NA (2002) Histone peptide-induced nasal tolerance: suppression of murine lupus. J Immunol 169:1126–1134
Fujio K, Okamoto A, Tahara H, Abe M, Jiang Y, Kitamura T, Hirose S, Yamamoto K (2004) Nucleosome-specific regulatory T cells engineered by triple gene transfer suppress a systemic autoimmune disease. J Immunol 173:2118–2125
Suen J-L, Chuang Y-H, Tsai B-Y, Yau PM, Chiang B-L (2004) Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum 50:3250–3259
Zinger H, Eilat E, Meshorer A, Mozes E (2003) Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW) F1 mice via active suppression. Int Immunol 15:205–214
Zhang X, Smith DS, Guth A, Wysocki LJ (2001) A receptor presentation hypothesis for T cell help that recruits autoreactive B cells. J Immunol 166:1562–1571
Monneaux F, Muller S (2002) Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum 46:1430–1438
Greidinger EL, Gazitt T, Jaimes KF, Hoffman RW (2004) Human T cell clones specific for heterogeneous nuclear ribonucleoprotein A2 autoantigen from connective tissue disease patients assist in autoantibody production. Arthritis Rheum 50:2216–2222
Riemekasten G, Langnickel D, Ebling FM, Karpouzas G, Kalsi J, Herberth G, Tsao BP, Henklein P, Langer S, Burmester GR, Radbruch A, Hiepe F, Hahn BH (2003) Identification and characterization of SmD183–119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies. Arthritis Rheum 48:475–485
Busser BW, Adair BS, Erikson J, Laufer TM (2003) Activation of diverse repertoires of autoreactive T cells enhances the loss of anti-dsDNA B cell tolerance. J Clin Invest 112:1361–1371
Deshmukh US, Gaskin F, Lewis JE, Kannapell CC, Fu SM (2003) Mechanisms of autoantibody diversification to SLE-related autoantigens. Ann NY Acad Sci 987:91–98
Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063–2073
Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK (1995) Structure and specificity of T-cell receptors expressed by pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 95:531–541
Andreassen K, Moens U, Nossent H, Marion TN, Rekvig OP (1999) Termination of human T cell tolerance to histones by presentation of histones and polyomavirus T antigen provided that T antigen is complexed with nucleosomes. Arthritis Rheum 42:2449–2460
Bieganowska KD, Ausubel LJ, Modabber Y, Slovik E, Messersmith W, Hafler DA (1997) Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med 185:1585–1594
Kammer GM, Perl, A, Richardson BC, Tsokos GC (2002) Abnormal T cell signal transduction in systemic lupus erythromatosus. Arthritis Rheum 46:1139–1154
Shlomchik MJ, Craft JE, Mamula MJ (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1:147–153
Eastcott JW, Schwartz RS, Datta SK (1983) Genetic analysis of the inheritence of B cell hyperactivity in relation to the development of autoantibodies and glomerulonephritis in NZB x SWR crosses. J Immunol 131:2232–2239
Dieker JW, van der Vlag J, Berden JH (2002) Triggers for anti-chromatin autoantibody production in SLE. Lupus 11:856–864
Kono DH, Theofilopoulos AN (2000) Genetic studies in systemic autoimmunity and aging. Immunol Res 21:111–122
Wakeland EK, Liu K, Graham RR, Behrens TW (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397–408
Mohan C, Alas E, Morel L, Ping Y, Wakeland EK (1998) Genetic dissection of SLE pathogenesis: Sle 1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosome. J Clin Invest 101:1362–1372
Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G, Kotzin BL (2001) Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 15:435–443
Harley JB, Moser KL, Gaffney PM, Behrens TW (1998) The genetics of human systemic lupus erythematosus. Curr Opin Immunol 10:690–696
Sobel ES, Satoh M, Chen Y, Wakeland EK, Morel L (2002) The major murine systemic lupus erythematosus susceptibility locus sle1 results in abnormal functions of both B and T cells. J Immunol 169:2694–2700
Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M (1991) Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 349:331–334
Chen C, Nagy Z, Radic MZ, Hardy RR, Huszar D, Camper SA, Weigert M (1995) The site and stage of anti-DNA B-cell deletion. Nature 373:252–255
Datta SK, Stollar BD, Schwartz RS (1983) Normal mice express idiotypes related to autoantibody idiotypes of lupus mice. Proc Natl Acad Sci USA 80:2723–2727
Conger JD, Pike BL, Nossal GJ (1987) Clonal analysis of the anti-DNA repertoire of murine B lymphocytes. Proc Natl Acad Sci USA 84:2931–2935
Ray SK, Putterman C, Diamond B (1996) Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci USA 93:2019–2024
Stewart A, Huang C, Long A, Stollar B, Schwartz R (1992) VH-gene representation in autoanitbodies reflects the normal B cell repertoire. Immunol Rev 128:101–122
Datta SK (2003) Major peptide autoepitopes for nucleosome-centered T and B cell interaction in human and murine lupus. Ann NY Acad Sci 987:79–90
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101:890–898
Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I (1997) Immunosuppressive effects of apoptotic cells. Nature 390:350–351
Kurosaka K, Takahashi M, Watanabe N, Kobayashi Y (2003) Silent cleanup of very early apoptotic cells by macrophages. J Immunol 171:4672–4679
Steinman RM, Turley S, Mellman I, Inaba K (2000) The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191:411–416
Mevorach D, Zhou JL, Song X, Elkon KB (1998) Systemic exposure to irradiated apoptotic cells induces autoanitbody production. J Exp Med 188:387–392
Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, Earp HS, Matsushima G, Reap EA (2002) Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 196:135–140
Rumore P, Steinman C (1990) Endogenous circulating DNA in systemic lupus erythematosus. Occurrences as multimeric complexes bound to histones. J Clin Invest 86:69–74
Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22:431–456
Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS (2001) Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 166:6444–6451
Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41:1241–1250
Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MGE, Kimberly RP (1996) FcYRIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 97:1348–1354
Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48:2888–2897
Vassilopoulos D, Kovacs B, Tsokos GC (1995) TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 155:2269–2281
Liossis S-N, Kovacs B, Dennis G, Kammer GM, Tsokos GC (1996) B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 98:2549–2557
Chen Z, Koralov SB, Kelsoe G (2000) Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J Exp Med 192:1339–1352
Datta SK (2000) Positive selection for autoimmunity. Nat Med 6:259–261
Vratsanos GS, Jung S, Park YM, Craft J (2001) CD4 (+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J Exp Med 193:329–337
Boackle SA, Holers VM, Chen X, Szakonyi G, Karp DR, Wakeland EK, Morel L (2001) Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 15:775–785
Yung R, Powers D, Johnson K, Amento E, Carr D, Laing T, Yang J, Chang S, Hemati N, Richardson B (1996) Mechanisms of drug induced lupus. II. T cells overexpressing LFA 1 becomes autoreactive and cause a lupus like disease in syngeneic mice. J Clin Invest 97:2866–2871
Bouzahzah F, Jung S, Craft J (2003) CD4+ T cells from lupus-prone mice avoid antigen-specific tolerance induction in vivo. J Immunol 170:741–748
Kretz-Rommel A, Rubin RL (1997) A metabolite of the lupus-inducing drug procainamide prevents anergy induction in T cell clones. J Immunol 158:4465–4470
Moutsopoulos JM, Boehm-Truitt M, Kassan SS, Chused TM (1977) Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J Immunol 119:1639–1644
Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294:1540–1543
Datta SK, Owen FL, Womack JE, Riblet RJ (1982) Analysis of recombinant inbred lines derived from autoimmune (NZB) and high leukemia (C58) strains: independent multigenic systems control B cell hyperactivity, retrovirus expression and autoimmunity. J Immunol 129:1539–1544
Sobel ES, Katagiri T, Katagiri K, Morris SC, Cohen PL, Eisenberg RA (1991) An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med 173:1441–1449
Mamula MJ, Fatenejad S, Craft J (1994) B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 152:1453–1461
Jongstra-Bilen J, Vukusic B, Boras K, Wither JE (1997) Resting B cells from autoimmune lupus-prone NZB and (NZB x NZW) F1 mice are hyper-responsive to T cell-derived stimuli. J Immunol 159:5810–5820
Lian Z-X, Kikuchi K, Yang G-X, Ansari AA, Ikehara S, Gershwin ME (2004) Expansion of bone marrow IFN-a-producing dendritic cells in New Zealand black (NZB) mice: high level expression of TLR9 and secretion of IFN-a in NZB bone marrow. J Immunol 173:5283–5289
Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA (1998) Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol 160:2539–2545
Singh RR, Ebling FM, Albuquerque DA, Saxena V, Kumar V, Giannini EH, Marion TN, Finkelman FD, Hahn BH (2002) Induction of autoantibody production is limited in nonautoimmune mice. J Immunol 169:587–594
Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061
Bagavant H, Thompson C, Ohno K, Setiady Y, Tung KSK (2002) Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. Int Immunol 14:1397–1406
Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ (1994) gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 180:157–163
Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L (1992) Molecular interaction mediating T-B lymphocyte collaboration in human lymphoid follicles. Role T cell-B cell activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol 149:3817–3826
Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ (1993) The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 151:2497–2510
Mohan C, Shi Y, Laman JD, Datta SK (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 154:1470–1480
Koshy M, Berger D, Crow MK (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98:826–837
Yi Y, McNerney M, Datta SK (2000) Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 165:6627–6634
Higuchi T, Aiba Y, Nomura T, Matsuda J, Mochida K, Suzuki M, Kikutani H, Honjo T, Nishioka K, Tsubata T (2002) Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol 168:9–12
Devi BS, Van Noordin S, Krausz T, Davies KA (1998) Peripheral blood lymphocytes in SLE—hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmunity 11:471–475
Blossom S, Gilbert KM (1999) Antibody production in autoimmune BXSB mice. CD40L expressing B cells need fewer signals for polyclonal antibody synthesis. Clin Exp Immunol 118:147–153
Grammer AC, McFarland RD, Heaney J, Darnell BF, Lipsky PE (1999) Expression, regulation and function of B cell-expressed CD154 in germinal centers. J Immunol 163:4150–4159
Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305–334
Appleman LJ, Boussiotis VA (2003) T cell anergy and costimulation. Immunol Rev 192:161–180
Heissmeyer V, NMacian F, Im S, Varma R, Feske S, Venuprasad K, Gu H, Liu Y-C, Dustin ML, Rao A (2004) Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 5:255–265
Lupher ML, Rao N, Eck MJ, Band H (1999) The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction. Immunol Today 20:375–382
Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC (1999) The tyrosine kinase negative regulator c-Cbl RING type, E2 dependent, ubiquitin-protein ligase. Science 286:309–312
Naramura M, Jang IK, Kole H, Huang F, Haines D, Gu H (2002) c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol 3:1192–1199
Bachmaier K, Krawczyk C, Kozieradzki I, Kong Y-Y, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, Le J, Ohashi PS, Sarosi I, Nishina H, Lipkowitz S, Penninger JM (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adapter Cbl-b. Nature 403:211–216
Enyedy EJ, Nambiar MP, Liossis SN, Dennis G, Kammer GM, Tsokos GC (2001) Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 44:1114–1121
Tsytsykova AV, Tsitsikov EN, Geha RS (1996) The CD40L promoter contains NF-AT-binding motifs which require AP-1 binding for activation of transcription. J Biol Chem 271:3763–3770
Schubert LA, King G, Cron RQ, Lewis DB, Aruffo A, Hollenbaugh D (1995) The human gp39 promoter: two distinct NF-AT-binding elements contribute independently to transcriptional activation. J Biol Chem 270:29624–29627
Ford GS, Barnhart B, Shone S, Covey LR (1999) Regulation of CD154 (CD40L) mRNA stability during T cell activation. J Immunol 162:4037–4044
Hamilton BJ, Genin A, Cron RQ, Rigby WF (2003) Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression. Mol Cell Biol 23:510–525
Jury EC, Kabouridis PS, Flores-Borja F, Mageed RA, Isenberg DA (2004) Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 113:1176–1187
Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, Tsokos GC (2004) Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in sytemic lupus erythematosus. J Immunol 172:7821–7831
Krawczyk C, Bachmaier K, Sasaki T, Jones GR, Snapper BS, Bouchard D, Kozieradzki I, Ohashi SP, Alt WF, Penninger MJ (2000) Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity 13:463–473
Sohn HW, Gu H, Pierce SK (2003) Cbl-b negatively regulates B cell antigen receptor signaling in mature B cells through ubiquitination of the tyrosine kinase Syk. J Exp Med 197:1511–1524
Anandasabapathy N, Ford GS, Bloom D, Holness C, Paragas V, Seroogy C, Skrenta H, Hollenhorst M, Fathman CG, Soares L (2003) GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 18:535–547
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197:711–723
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100:2601–2605
Vallin H, Perers A, Alm GV, Ronnblom L (1999) Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 163:6306–6313
Kalled SL, Cutler AH, Burkly LC (2001) Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment. J Immunol 167:1740–1747
Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:595–598
Kim SJ, Gershov D, Ma X, Brot N, Elkon KB (2002) I-PLA (2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 196:655–665
Jiang N, Reich CF 3rd, Monestier M, Pisetsky DS (2003) The expression of plasma nucleosomes in mice undergoing in vivo apoptosis. Clin Immunol 106:139–147
Licht R, van Bruggen MC, Oppers-Walgreen B, Rijke TP, Berden JH (2001) Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration. Arthritis Rheum 44:1320–1330
Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, Krieg AM (2003) CpG Oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 63:394–399
Radic MZ, Weigert M (1994) Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 12:487–520
Ando DG, Sercarz EE, Hahn BH (1987) Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J Immunol 138:3185–3190
Gavalchin J, Datta SK (1987) The NZB x SWR model of lupus nephritis. II. Autoantibodies deposited in renal lesions show a restricted idiotypic diversity. J Immunol 138:138–148
Rovere P, Sabbadini MG, Vallinoto C, Fascio U, Recigno M, Crosti M, Ricciardi-Castagnoli P, Balestrieri G, Tincani A, Manfredi AA (1999) Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: role of opsonizing anti-beta2-glycoprotein I antibodies. Arthritis Rheum 42:1412–1420
Peng SL, McNiff JM, Madaio MP, Ma J, Owen MJ, Flavell RA, Hayday AC, Craft J (1997) alpha beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol 158:2464–2470
Kaliyaperumal A, Michaels MA, Datta SK (1999) Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162:5775–5783
Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D (1997) Long-term iinhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 159:3104–3108
Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu Y-X (2002) Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 8:1405–1411
Early GS, Zhao W, Burns CM (1996) Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice: response correlates with the absence of an anti-antibody response. J Immunol 157:3159–3164
Wang X, Huang W, Mihara M, Sinha J, Davidson A (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168:2046–2053
Shiono H, Roxanis I, Zhang W, Sims GP, Meager A, Jacobson LW, Liu JL, Matthews I, Wong YL, Bonifati M, Micklem K, Stott DI, Todd JA, Beeson D, Vincent A, Willcox N (2003) Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann NY Acad Sci 998:237–256
Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, Pirskanen R, Lefvert AK (2002) Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 130:224–232
Cedeno S, Cifarelli DF, Blasini AM, Paris M, Placeres F, Alonso G, Rodriguez MA (2003) Defective activity of ERK-1 and ERK-2 mitogen-activated protein kinases in peripheral blood T lymphocytes from patients with systemic lupus erythematosus: potential role of altered coupling of Ras guanine nucleotide exchange factor hSos to adapter protein Grb2 in lupus T cells. Clin Immunol 106:41–49
Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA (2003) Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 48:1343–1354
Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of systemic lupus erythematosus. J Exp Med 181:839–844
Van Laethem F, Baus E, Smyth LA, Andris F, Bex F, Urbain J, Kioussis D, Leo O (2001) Glucocorticoids attenuate T cell receptor signaling. J Exp Med 193:803–814
Niculescu F, Nguyen P, Niculescu T, Rus H, Rus V, Via CS (2003) Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Arthritis Rheum 48:1071–1079
Van Parijs L, Abbas AK (1998) Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243–248
Lenardo MJ (2003) Molecular regulation of T lymphocyte homeostasis in the healthy and diseased immune system. Immunol Res 27:387–398
Rathmell JC, Thompson CB (2002) Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 109:S97–S107
Green DR, Droin N, Pinkoski M (2003) Activation-induced cell death in T cells. Immunol Rev 193:70–81
Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33:29–55
Marrack P, Kappler J (2004) Control of T cell viability. Annu Rev Immunol 22:765–787
Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626–629
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190–195
Kirchhoff S, Muller WW, Li-Weber M, Krammer PH (2000) Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur J Immunol 30:2765–2774
Van Parijs L, Refaeli Y, Abbas AK, Baltimore D (1999) Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity 11:763–770
Wu W, Rinaldi L, Fortner KA, Russell JQ, Tschopp J, Irvin C, Budd RC (2004) Cellular FLIP long form-transgenic mice manifest a Th2 cytokine bias and enhanced allergic airway inflammation. J Immunol 172:4724–4732
Nachmias B, Ashhab Y, Ben-Yehuda D (2004) The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 14:231–243
Jesenberger V, Jentsch S (2002) Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3:112–121
Salvador JM, Hollander MC, Nguyen AT, Kopp JB, Barisoni L, Moore JK, Ashwell JD, Fornace AJ Jr (2002) Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 16:499–508
Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S (1994) Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 73:109–114
Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, Harris AW (1991) Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88:8661–8665
Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151
Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcon-Segovia D, Steinsson K, Alarcon-Riquelme ME (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666–669
Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP (1999) Impaired Fas response and autoimmunity in Pten+/- mice. Science 285:2122–2125
Chikuma S, Bluestone JA (2003) CTLA-4 and tolerance: the biochemical point of view. Immunol Res 28:241–253
Lawson BR, Baccala R, Song J, Croft M, Kono DH, Theofilopoulos AN (2004) Deficiency of the Cyclin Kinase Inhibitor p21 (WAF-1/CIP-1) Promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J Exp Med 199:547–557
Drappa J, Kamen LA, Chan E, Georgiev M, Ashany D, Marti F, King PD (2003) Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice. J Exp Med 198:809–821
Theofilopoulos AN, Dixon FJ (1985) Murine models of systemic lupus erythematosus. Adv Immunol 37:269–390
Zhou T, Su X, Wu J, Cheng J (1996) Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. Clin Immunol Immunopathol 80:S2–S14
Vaishnaw AK, Toubi E, Ohsako S, Drappa J, Buys S, Estrada J, Sitarz A, Zemel L, Chu JL, Elkon KB (1999) The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Arthritis Rheum 42:1833–1842
Kovacs B, Vassilopoulos D, Vogelgesang SA, Tsokos GC (1996) Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol 81:293–302
Xu L, Zhang L, Yi Y, Kang HK, Datta SK (2004) Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 10:411–415
Pablos JL, Santiago B, Carreira PE, Galindo M, Gomez-Reino JJ (1999) Cyclooxygenase-1 and −2 are expressed by human T cells. Clin Exp Immunol 115:86–90
Lin Z, Fillmore GC, Um TH, Elenitoba-Johnson KS, Lim MS (2003) Comparative microarray analysis of gene expression during activation of human peripheral blood T cells and leukemic Jurkat T cells. Lab Invest 83:765–776
Mitchell T, Hildeman D, Kedl R, Teague T, Schaefer B, White J, Zhu Y, Kappler J, Marrack P (2001) Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol 2:397–402
Stack E, DuBois RN (2001) Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am 30:1001–1010
Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (2002) Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94:1745–1757
Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML (2001) Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 276:48997–49002
Jones RG, Elford AR, Parsons MJ, Wu L, Krawczyk CM, Yeh WC, Hakem R, Rottapel R, Woodgett JR, Ohashi PS (2002) CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med 196:335–348
Berg-Brown NN, Gronski MA, Jones RG, Elford AR, Deenick EK, Odermatt B, Littman DR, Ohashi PS (2004) PKCq signals activation versus tolerance In Vivo. J Exp Med 199:743–752
Schirmer M, Vallejo AN, Weyand CM, Goronzy JJ (1998) Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28-T cells from rheumatoid arthritis patients. J Immunol 161:1018–1025
Sharief MK, Semra YK (2001) Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 119:358–364
Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615–623
Zheng Y, Vig M, Lyons J, Van Parijs L, Beg AA (2003) Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med 197:861–874
Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsovics M, Tschopp J (2000) The caspase-8 inhibitor FLIP promotes activation of NF-kB and Erk signaling pathways. Curr Biol 10:640–648
Dixon DA, Balch GC, Kedersha N, Anderson P, Zimmerman GA, Beauchamp RD, Prescott SM (2003) Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J Exp Med 198:475–481
Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145–182
Parfenova H, Parfenov VN, Shlopov BV, Levine V, Falkos S, Pourcyrous M, Leffler CW (2001) Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am J Physiol Cell Physiol 281:C166–C178
Ballif BA, Mincek NV, Barratt JT, Wilson ML, Simmons DL (1996) Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. Proc Natl Acad Sci USA 93:5544–5549
Lander SA, Wallace DJ, Weisman MH (2002) Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 11:340–347
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533
Acknowledgements
These studies were supported by National Institutes of Health grants R37-AR39157 and RO1-AI41985 to S.K.D.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Datta, S.K., Zhang, L. & Xu, L. T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens. J Mol Med 83, 267–278 (2005). https://doi.org/10.1007/s00109-004-0624-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-004-0624-2